迈之灵治疗视网膜静脉阻塞

Clinical therapy of retinal vein occlusion with aescuven forte

目的:观察迈之灵治疗视网膜静脉阻塞的疗效和安全性。方法:41例(41眼)临床诊断为视网膜静脉阻塞病人被随机分为2组,迈之灵组23例(23眼),予迈之灵2片,po,bid,4wk为一疗程,连续3个疗程。丹参组18例(18眼),先予丹香冠心注射液16mL加入5%葡萄糖注射液(或氯化钠注射液)500mL中,静脉滴注,qd,1wk后改为丹参片,3片,po,tid,连续服用11wk。观察治疗前后视力、视野及视网膜电流图的动态变化,并评定疗效。结果:治疗wk4,8末,迈之灵组视力提高优于丹参组(P<0.05,P<0.01)。治疗wk4末,迈之灵组渗出、出血吸收率61%,高于丹参组的28%(P<0.05);视网膜血管渗漏改善明显,优于丹参组(P<0.05)。治疗wk12末,迈之灵组暗适应眼最大电反应的b波振幅及b/a值与治疗前相比明显提高(P<0.01),且2组有差异(P<0.05,P<0.01);迈之灵组总有效率91%,丹参组56%,2组疗效有显著差异(P<0.05),均未见不良反应。结论:迈之灵治疗视网膜静脉阻塞有效、安全,早期疗效优于丹参。

AIM： To investigate the therapeutic effect and safety of aescuven forte on retinal vein occlusion （RVO）. METHODS： Forty-one patients （41 eyes） with RVO were divided into two groups randomly： 23 patients （23 eyes） in aescuven forte group receiving aescuven forte, 2 tablets, po, tid, 4 wk as a course altogether for 12 wk, and 18 patients （18 eyes） in Salvia miltiorrhiza group receiving Danxiang Guanxin injection 16 mL ＋ 5 % glucose injection （or sodium chloride injection） 500 mL, iv, gtt, qd for 1 wk followed by Salvia miltiorrhiza tablets, 3 tablets, po, tid, for 11 wk. The visual activity, visual field and electroretinogram were observed before and 4, 8, 12 wk after the treatment. RESULTS： At the end of 4, 8 wk after treatment, the improvement of visual activity in aescuven forte group was much better than that in Salvia miltiorrhiza group with statistical difference between two groups（P〈0.05, P〈0.01）. At the end of 4 wk after treatment, the absorbency of bleeding and exudation of aescuven forte group was 61%, higher than that of Salvia miltiorrhiza group （28 %, P 〈 0.05）. The maximum electroneflex amplitude of dark adaptation eye b wave and b/a in aescuven forte group were meliorated 12 wk later （P 〈 0.01） showing more improvement than those in Salvia miltiorrhiza group （P 〈 0.05, P 〈 0.01）. The total effective rates were 91% and 56% in aescuven forte and Salvia miltiorrhiza group respectively. There was a significant statistical difference in clinic efficacies between the two groups （P 〈 0.05）. No obvious adverse reactions occurred in both groups. CONCLUSION： Aescuven forte is efficient and safe in the treatment of RVO and especially superior to Salvia miltiorrhiza in the early phase of the treatment.